EGFR and non-small cell lung carcinoma: Tyrosine kinase inhibitors (TKI) targeting EGFR, including gefitinib and erlotinib, have become the standard first line therapy for patients with advanced non-small cell lung cancer (NSCLC) that harbor activating EGFR mutations [9], [10].